Search

Displaying results 4721 - 4730 of 10000 in total
  1. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold

  2. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.

  3. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  4. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. … Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

  5. Drug

    Evofosfamide

    go.drugbank.com/drugs/DB06091
    Investigational

    TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. … TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or "hypoxic" conditions typical of solid tumor cancer cells.

  6. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. … HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

  7. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  8. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix is a synthetically derived thyroid hormone replacement preparation. … It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues.

  9. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  10. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].